Ocugen CEO @drsmusunuri joined @BBC Correspondent @JamesTGallagher at Cell & Gene Leaders Live to discuss our modifier gene therapy platform and its potential to address vision loss across a broader patient population.
#GeneTherapy #Biotech $OCGN
Today, at the @Stifel 2026 Healthcare Conference, Ocugen CEO @drsmusunuri highlighted our novel modifier #genetherapy platform and three Phase 3 investigational assets in NYC. #Biotech
Watch the replay: bit.ly/4zdvc2f
$OCGN
Ocugen is expanding the potential reach of #OCU400 for #retinitispigmentosa through an exclusive licensing agreement with Celairis Therapeutics for #commercialization across Australia, New Zealand, and ASEAN markets with an estimated 725M+ people, following potential U.S. approval. $OCGN
🔗bit.ly/3Vk1ue6
Today, CEO @drsmusunuri highlighted 3Q 2026 milestones:
• #OCU400: Provisional Approval and Priority Designation in the Bahamas and a licensing agreement in MENA + topline results from Phase 3 anticipated in 1Q 2027
• #OCU410: Phase 3 dosing initiated
• $84.6M in cash and cash equivalents; runway into 2028
Read: bit.ly/4iW3gLo
#QuarterlyUpdate $OCGN
Ocugen is taking part in two key industry events this November!
CEO @drsmusunuri will participate in the Stifel 2026 Healthcare Conference and Cell & Gene Leaders Live 2026. Read more: bit.ly/4ss67Pm
#HealthcareInnovation #GeneTherapy $OCGN
Mark your calendars! Join us on Wednesday, November 4, at 8:30 a.m. ET for a business update and 3Q 2026 financial results. Conference call and webcast details: bit.ly/4A88WIj
#QuarterlyEarnings #Biotech #InvestorRelations $OCGN
Ocugen and Roots Pharmaceutical have completed a licensing agreement for #OCU400 in MENA, advancing global commercialization.
Terms include up to $4M in upfront and initial development milestones, $255M in potential sales milestones, and 22% royalties on net sales. $OCGN
Read more: bit.ly/47OVm06
An important milestone at #AAO2026! During the @aao_ophth Annual Meeting, Raj K. Maturi, MD, presented 12-month safety and efficacy results from our Phase 2 ArMaDa trial evaluating #OCU410 for #geographicatrophy, supporting its continued advancement in Phase 3. #GeneTherapy $OCGN
Read more from @ophth_advisor: bit.ly/4e9Qh67
Innovation took center stage at #CGMesa26.
Ocugen CEO @drsmusunuri joined investors and industry leaders to discuss the future of #GeneTherapy and the road to commercialization as we advance three Phase 3 programs designed to address multiple disease pathways, not just a single mutation, with the potential to treat major blindness diseases. @alliancerm #InvestorRelations $OCGN
Jolanda Crombach, MSc PharmD, has been appointed General Manager of our newly established European affiliate, headquartered in Amsterdam, to support our three Phase 3 novel modifier #GeneTherapy programs and potential #commercialization. #Biotech $OCGN
Read more: bit.ly/4y1ImyI
Ocugen will present its novel modifier #genetherapy platform at upcoming scientific conferences, including EIS 2026, the 26th @EURETINA Congress 2026, and the @aao_ophth Annual Meeting 2026.
Read more: bit.ly/3Tww5UQ
#EURETINA26 #AAO2026 #Ophthalmology $OCGN
Ocugen CEO @drsmusunuri will participate in @HCWCO: #Biotech on Tap and the Cell & Gene Meeting on the Mesa this October, sharing updates on our gene therapy programs with the investment community. @alliancerm #CGMesa26 #InvestorRelations $OCGN
Read: bit.ly/3VC4ana
Hear from CEO @drsmusunuri on how the LARTA Board in the Bahamas is enabling access to #OCU400 for #retinitispigmentosa through an Expanded Access Program with #commercialpricing and its potential to help patients worldwide. @MOHW242 #Genetherapy $OCGN 🔗 bit.ly/4xNFDZR
#OCU400, our #genetherapy for #retinitispigmentosa, received provisional approval and priority designation from the LARTA Board in the Bahamas, a significant step as we advance our mission globally. @MOHW242 $OCGN #CommercialPricing 🔗bit.ly/4xNFDZR
Ocugen CEO @drsmusunuri will join industry leaders at #CGMesa26 for the “Leadership Perspectives: Beyond Breakthrough” panel on October 6 in Phoenix, AZ.
Learn more: meetingonthemesa.com
@alliancerm #Biotech #GeneTherapy
📽️ A full day at the #CGMesa26 in 30 seconds.
Register today ➡️ meetingonthemesa.com
Join 1,500+ executives, investors, developers, and manufacturers from across the cell and gene therapy sector on October 5-7, 2026, at the Arizona Biltmore in Phoenix.
What is #OCU410, and what does Phase 3 clinical trial mean? OCU410 is an investigational gene therapy with the potential to treat #geographicatrophy secondary to #dAMD.
Swipe through to learn about OCU410 and Phase 3. Like, follow, and repost if you found this info helpful!
We participated in the @HCWCO 28th Annual Global Investment Conference, where CEO @drsmusunuri reflected on our progress and shared what’s ahead for #Ocugen as we work to shape the future of vision.
Watch the replay: bit.ly/46rSohq
$OCGN #GeneTherapy #Biotech





















